The bar graph illustrates the financial investments allocated for research by five prominent pharmaceutical companies in the years 2012, 2018, and projected for 2022.
Overall, it is evident that there has been a general upward trajectory in research spending across all companies over the specified years, with Novas consistently leading the expenditure.
In 2012, Novas recorded a research expenditure of $8 billion, which increased significantly to $15 billion by 2018. The forecast for 2022 indicates that Novas will allocate a remarkable $50 billion, marking the most substantial growth among the companies surveyed. Fleming also demonstrated a notable increase, with spending rising from $5 billion in 2012 to $12 billion in 2018, and an anticipated expenditure of $35 billion in 2022. Biopharm, while starting from a lower base of $3 billion in 2012, matched Fleming’s growth by reaching $12 billion in 2018 and is projected to spend $30 billion in 2022.
